Wayne Katon, MD; Peter Roy-Byrne, MD
Potential Financial Conflicts of Interest: Consultancies: W. Katon (Eli Lilly Inc.), P. Roy-Byrne (Alza, Cephalon, GlaxoSmithKline, Forest Pharmaceuticals, Eli Lilly Inc., Jannsen Research Foundation, Jazz Pharmaceuticals, Pfizer Inc., Pharmacia Corp., Solvay, Roche, Wyeth-Ayerst); Honoraria: W. Katon (Eli Lilly Inc., Pfizer Inc., Forest Pharmaceuticals, Wyeth), P. Roy-Byrne (GlaxoSmithKline, Forest Pharmaceuticals, Novartis, Pfizer Inc., Pharmacia Corp., Wyeth-Ayerst); Grants received: P. Roy-Byrne (GlaxoSmithKline, Pfizer Inc., Forest Pharmaceuticals).
Requests for Single Reprints: Wayne Katon, MD, Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Box 356560, 1959 NE Pacific Street, Seattle, WA 98195-6560; e-mail, firstname.lastname@example.org.
Current Author Addresses: Dr. Katon: Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Box 356560, 1959 NE Pacific Street, Seattle, WA 98195-6560.
Dr. Roy-Byrne: Harborview Medical Center, 2HH7 Harborview Medical Center, 325 Ninth Avenue, Seattle, WA 98104.
Katon W, Roy-Byrne P. Anxiety Disorders: Efficient Screening Is the First Step in Improving Outcomes. Ann Intern Med. 2007;146:390–392. doi: 10.7326/0003-4819-146-5-200703060-00011
Download citation file:
Published: Ann Intern Med. 2007;146(5):390-392.
Healthcare Delivery and Policy, Prevention/Screening.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use